BJL
NBIX icon

Brighton Jones LLC’s Neurocrine Biosciences NBIX Stock Holding History

Brighton Jones LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.16M Sell
12,830
-6,042
-32% -$896K 0.04% 283
2026
Q1 		$2.49M Buy
+18,872
New +$2.5M 0.05% 230
2025
Q4 		– Sell
-10,216
Closed -$1.43M – 631
2025
Q3 		$1.43M Buy
10,216
+7,426
+266% +$1.01M 0.03% 296
2025
Q2 		$351K Buy
+2,790
New +$320K 0.01% 662

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brighton Jones LLC's NBIX Position: Q2 2026 in Review

Brighton Jones LLC reduced its Neurocrine Biosciences (NBIX) stake by 32% in Q2 2026, selling an estimated $896K and leaving 12,830 shares worth $2.16M. The position accounts for 0.04% of the portfolio, ranked #283.

Brighton Jones LLC first reported a position in NBIX in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.49M in Q1 2026. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Brighton Jones LLC held 12,830 shares of Neurocrine Biosciences worth $2.16M as of Q2 2026.
  • Brighton Jones LLC sold 6,042 Neurocrine Biosciences shares in Q2 2026, an estimated $896K.
  • Neurocrine Biosciences made up 0.04% of Brighton Jones LLC's portfolio in Q2 2026, its #283 holding.
  • Brighton Jones LLC first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Brighton Jones LLC's Neurocrine Biosciences position peaked at $2.49M in Q1 2026.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.